Epidemiology and Clinical Presentation of Ovarian Cancer

Early Diagnosis and Treatment of Cancer Series: Ovarian Cancer

Volumn , Issue , 2010, Pages 1-15

  Jhamb, Namita ^a   Lambrou, Nicholas C ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b MIAMI CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83655194912     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4685-1.50006-8     Document Type: Chapter

References (65)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Berek J Epithelial ovarian cancer. Practical Gynecologic Oncology 2005, 443-509. Lippincott Williams & Wilkins, Philadelphia. 4th ed. J.S. Berek, N.F. Hacker (Eds.).
3. Ozols R, Rubin S, Thomas G, Robboy S Principles and Practice of Gynecologic Oncology 2005, 895-987. Lippincott Williams & Wilkins, Philadelphia. 4th ed. W. Hoskins (Ed.).
4. Ozols RF, Bundy BN, Greer BE, Gynecologic Oncology Group, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21(17):3194-3200.
5. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001, 19(4):1001-1007.
6. Parham G, Phillips JL, Hicks ML, et al. The National Cancer Data Base report on malignant epithelial ovarian carcinoma in African-American women. Cancer 1997, 80(4):816-826.
7. Hartge P, Whittemore AS, Itnyre J, et al. Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet Gynecol 1994, 84:760-764.
8. Fathalla MF Incessant ovulation-a factor in ovarian neoplasia?. Lancet 1971, 2(7716):163.
9. Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003, 104:228-232.
10. Greene MH, Clark JW, Blayney DW The epidemiology of ovarian cancer. [Review]. Semin Oncol 1984, 11(3):209-226.
11. Pelucchi C, Galeone C, Talamini R, et al. Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 2007, 196(1):83.e1-83.e7.
12. Franceschi S, La Vecchia C, Booth M, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991, 49(1):57-60.
13. La Vecchia C Oral contraceptives and ovarian cancer: an update, 1998-2004. [Review]. Eur J Cancer Prev 2006, 15(2):117-124.
14. Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991, 49(1):61-65.
15. Gross TP, Schesseleman JJ The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994, 83(3):419-424.
16. Rosenblatt KA, Thomas DB Lactation and the risk of epithelial ovarian cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1993, 22(2):192-197.
17. Gwinn ML, Lee NC, Rhodes PH, et al. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 1990, 43(6):559-568.
18. Ness B, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002, 155(3):217-224.
19. Rossing MA, Tang MT, Flagg EW, et al. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004, 160(11):1070-1078.
20. Shoham Z Epidemiology, etiology and fertility drugs in ovarian epithelial carcinoma: Where are we today?. Fertil Steril 1994, 62:433-448.
21. Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002, 77(2):324-327.
22. Venn A, Jones P, Quinn M, Healy D Characteristics of ovarian and uterine cancers in a cohort of in vitro fertilization patients. Gynecol Oncol 2001, 82(1):64-68.
23. Kaufman DW, Kelly JP, Welch WR, et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989, 130(6):1142-1451.
24. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002, 288(3):334-341. Erratum in: JAMA 288(20):2544, 2002.
25. Moorman PG, Schildkraut JM, Calingaert B, et al. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 2005, 193(1):76-82.
26. Glud E, Kjaer SK, Thomsen BL, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004, 164(20):2253-2259.
27. Anderson GL, Judd HL, Kaunitz AM, et al. Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative Randomized Trial. JAMA 2003, 290(13):1739-1748.
28. Lacey JV, Brinton LA, Leitzmann MF, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006, 98(19):1397-1405.
29. Boyd J Specific keynote: hereditary ovarian cancer: what we know. [Review]. Gynecol Oncol 2003, 88(1 Pt 2):S8-S10. discussion S11-S13.
30. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302(5645):643-646.
31. Szabo CI, King MC Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997, 60(5):1013-1020.
32. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998, 178(4):670-677.
33. Robles-Diaz L, Goldfrank DJ, Kauff ND, et al. Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer 2004, 3(3-4):259-264.
34. Lynch HT, Casey MJ, Lynch J, et al. Genetics and ovarian carcinoma. [Review]. Semin Oncol 1998, 25(3):265-280.
35. Risch HA, Jain M, Marrett LD, Howe GR Dietary fat intake and risk of epithelial ovarian cancer. J Natl Cancer Inst 1994, 86(18):1409-1415.
36. Cramer DW, Liberman RF, Titus-Ernstoff L, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999, 81(3):351-356.
37. Wong C, Hempling RE, Piver MS, et al. Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control study. Obstet Gynecol 1999, 93(3):372-376.
38. Whittemore AS, Wu ML, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988, 128(6):1228-1240.
39. Olsen CM, Green AC, Whiteman DC, et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007, 43:690-709.
40. Chang ET, Canchola AJ, Lee VS, et al. Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort. Cancer Causes Control 2007, 18(1):91-103.
41. Peterson NB, Trentham-Dietz A, Newcomb PA, et al. Alcohol consumption and ovarian cancer risk in a population-based case-control study. Int J Cancer 2006, 119(10):2423-2437.
42. Risch HA, Howe GR Pelvic inflammatory disease and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995, 4(5):447-451.
43. Yoshikawa H, Jimbo H, Okada S, et al. Prevalence of endometriosis in ovarian cancer. Gynecol Obstet Invest 2005, 50(Suppl 1):11-17.
44. Webb PM, Purdie DM, Grover S, et al. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol 2004, 92(1):232-239.
45. Olson SH, Mignone L, Nakraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001, 98(2):212-217.
46. Munoz KA, Harlan LC, Trimble EL Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997, 15(11):3408-3415.
47. Nguyen HN, Averette HE, Hoskins W, et al. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993, 72(10):3007-3011.
48. Chan JK, Urban R, Cheung MK, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer 2006, 95(10):1314-1320.
49. Rodriguez M, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer 1994, 73(4):1245-1250.
50. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993, 71(2 Suppl):606-614.
51. Sorbe B, Frankendal B, Veress B Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 1982, 59(5):576-582.
52. Sherman ME, Mink PJ, Curtis R, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004, 100(5):1045-1052.
53. Heintz A, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. Int J Gynecol Obstet 95(Suppl 1):S161-S192.
54. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999, 72(3):278-287.
55. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 2006, 103(2):559-564.
56. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170(4):974-979. discussion 979-980.
57. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20(5):1248-1259.
58. Cooper BC, Sood AK, Davis CS, et al. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS 2006, 114(5):359-363.
59. Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2003, 13(2):120-124.
60. Markman M, Federico M, Liu PY, et al. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006, 103(1):195-198.
61. Bast RC, Xu FJ, Yu YH, et al. CA 125: the past and the future. [Revised]. Int J Biol Markers 1998, 13(4):179-187.
62. Kimmig R, Wimberger P, Hillemanns P, et al. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells. Gynecol Oncol 2002, 84(1):21-31.
63. Eltabbakh GH, Belinson JL, Kennedy AW, et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997, 80(5):892-898.
64. Wong YF, Cheung TH, Lam SK, et al. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol Obstet Invest 1995, 40(3):209-212.
65. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21(2):283-290.